Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
news
Notification of Acquisition of Own Securities
The Company provides below details of an acquisition of its own securities.
As permitted under Delaware law and under the Company's 2001 Equity Incentive Plan, on January 17, 2007 the Company accepted 25,614 common shares, valued at 94.5p per share (the "Consideration Shares"), as consideration for the exercise of options to purchase 674,968 common shares granted under the Company's 2001 Equity Incentive Plan.
The Consideration Shares will be held by the Company as treasury shares. Consequently, the number of treasury shares held by the Company following this transaction is 25,614.
On January 8 2007, 2,500 options to purchase common shares were exercised by an employee of the Company.
The number of issued common shares of the Company following these transactions, less the shares held in treasury, is 46,971,796.
This notification relates to a transaction notified in accordance with Listing Rule 12.4.6R.